Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Diabetes Combo Needs More Clinical Data, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Even though both components are already marketed, firm might have to do another study for fixed-dose combination of DPP-4 inhibitor saxagliptin and SGLT2 inhibitor dapagliflozin.

Advertisement

Related Content

Keeping Track: US FDA Accepts Ertugliflozin, Extends Reviews Of Abaloparatide, New Keytruda Claim
Keeping Track: Novartis, Calardius Pick Up Speed; ADMA Stumbles
AstraZeneca's Hudson Optimistic On Return To Growth In 2017
SGLT2 Inhibitors' Warning On Ketoacidosis Recommends Drug Holidays
AstraZeneca Says Durvalumab Less Likely To Get Early Approval
Keeping Track: Pfizer, AstraZeneca Get Complete Responses; FDA Sees Breakthroughs In Live Biotherapeutics
FDA Warning On SGLT-2 Drugs Raises Specter Of Labeling Change
Alogliptin, Saxagliptin Show Neutral CV Effects In Outcomes Studies
AstraZeneca/Bristol's Diabetes Drug Onglyza Cleared

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS077881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel